CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 53 enrolled
Drug / intervention
Dasatinib +1 moredrug
Likely dose
Dasatinib 70 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00826449
NCT00826449Phase 2Completed
CompareCT.gov

Phase I-II Study of Dasatinib and Erlotinib in Non-Small Cell Lung Cancer

M.D. Anderson Cancer Center·interventional·Posted Jan 22, 2009·Updated Jun 28, 2016

In Brief

A Phase 2 clinical trial evaluating Dasatinib and Erlotinib for Lung Cancer and Non-Small Cell Lung Cancer. Completed, enrolled 53 participants across 1 site.

Detailed Summary

The goal of the Phase I portion of this study is to find the highest tolerable dose of the combination of dasatinib and erlotinib hydrochloride that can be given to patients with advanced solid tumors. The goal of the Phase II portion of this study is to learn if this combination is effective when given to patients with non-small cell lung cancer. The safety of this combination will be studied in both phases.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer, Non-Small Cell Lung Cancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb, OSI Pharmaceuticals

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 22, 2009
Enrollment StartFeb 1, 2009
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 17.4 years ago

Interventions

Dasatinibdrug

Starting dose of 70 mg by mouth daily for 21 day cycle.

Erlotinibdrug

150 mg by mouth daily every 21 day cycle.